Page last updated: 2024-12-08

2-benzyloxybenzaldehyde

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID344784
CHEMBL ID61500
SCHEMBL ID433401
MeSH IDM0442988

Synonyms (41)

Synonym
BB 0217893
o-benzylsalicylaldehyde
2-(benzyloxy)benzaldehyde
nsc-401884
benzaldehyde, o-(benzyloxy)-
nsc401884
5896-17-3
o-(benzyloxy)benzaldehyde
benzaldehyde, 2-(phenylmethoxy)-
2-benzyloxybenzaldehyde, 98%
AK-968/13039179
STK189373
2-benzyloxybenzaldehyde
CHEMBL61500
2-benzyloxy-benzaldehyde
2-phenylmethoxybenzaldehyde
AKOS000120947
A832090
FT-0611315
bdbm93343
integrase inhibitor, r2{4}
BBL023517
SCHEMBL433401
AB00308253-03
o-benzyloxybenzaldehyde
benzyloxybenzaldehyde
salicylaldehyde benzyl ether
cambridge id 7183859
DTXSID30322707
mfcd00016583
J-506248
sr-01000253788
SR-01000253788-1
CS-W008921
NCGC00321645-01
SY037882
Z26335724
EN300-15513
STR03139
2-(benzyloxy)benzaldehyde; nsc 401884; o-benzylsalicylaldehyde
nsc 401884
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gag-Pol polyproteinHIV-1 M:B_HXB2RIC50 (µMol)1.75000.00060.91418.3200AID1799907
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (2)

Processvia Protein(s)Taxonomy
viral life cycleGag-Pol polyproteinHIV-1 M:B_HXB2R
establishment of integrated proviral latencyGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptidase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
integrase activityGag-Pol polyproteinHIV-1 M:B_HXB2R
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID231756Ratio of cAMP-elevating activity relative to forskolin2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.
AID264897Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil at 10 uM2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID264895Formation of fMLP-induced superoxide in Sprague-Dawley rat neutrophil at 30 uM per 10^6 cells after 30 min2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID1544945Inhibition of NO711 binding to mouse GAT1 expressed in HEK293 cell membranes assessed as residual binding at 1 uM incubated for 4 hrs in presence of NO711 by LC-ESI-MS/MS analysis relative to control2019Bioorganic & medicinal chemistry, 07-01, Volume: 27, Issue:13
Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1).
AID264896Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil at 3 uM2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID179777In vitro inhibitory effect on neutrophil superoxide formation isolated from pentobarbital-anesthetized rats2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.
AID264898Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil at 30 uM2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID264913Increase in cAMP level in Sprague-Dawley rat neutrophil2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID264899Inhibition of fMLP-induced superoxide formation in Sprague-Dawley rat neutrophil2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID264894Formation of fMLP-induced superoxide in Sprague-Dawley rat neutrophil at 10 uM per 10^6 cells after 30 min2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID34591Effect of compound on cellular c-AMP levels by activation of Adenylate cyclase2001Bioorganic & medicinal chemistry letters, Aug-06, Volume: 11, Issue:15
Benzyloxybenzaldehyde analogues as novel adenylyl cyclase activators.
AID1602658Inhibition of mouse GAT-1 assessed as percentage of remaining specific binding of NO711 at 1 uM after 4 hrs by LC-ESI-MS/ms analysis relative to control2019Bioorganic & medicinal chemistry, 04-01, Volume: 27, Issue:7
Screening oxime libraries by means of mass spectrometry (MS) binding assays: Identification of new highly potent inhibitors to optimized inhibitors γ-aminobutyric acid transporter 1.
AID264893Formation of fMLP-induced superoxide in Sprague-Dawley rat neutrophil at 3 uM per 10^6 cells after 30 min2006Bioorganic & medicinal chemistry letters, May-15, Volume: 16, Issue:10
Synthesis of (2E)-3-{2-[(substituted benzyl)oxy]phenyl}acrylaldehydes as novel anti-inflammatory agents.
AID1799907Inhibition Assay from Article 10.1021/cc9001026: \\Solid phase synthesis of novel pyrrolidinedione analogs as potent HIV-1 integrase inhibitors.\\
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (45.45)29.6817
2010's5 (45.45)24.3611
2020's1 (9.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.05

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.05 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.05)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]